Skip to main content
SpringerLink
Log in

Evolution of definitive external beam radiation therapy in the treatment of prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Although the clinical significance of a diagnosis of prostate cancer for some men is debated, for many men it leads to significant morbidity and mortality. Radical treatment of clinically localized prostate cancer has been shown to improve survival in men with intermediate or high-risk disease. There is no high level evidence to support the superiority of radical prostatectomy, with or without adjuvant or salvage external beam radiotherapy in comparison to definitive radiotherapy with or without androgen deprivation, and the choice should be individualized. External beam radiation therapy practices are in constant evolution, and numerous strategies have been investigated to improve either efficacy or reduce toxicity, or both.

Methods

Randomized controlled trials investigating strategies to improve efficacy, reduce toxicity, or both of external beam radiotherapy have been reviewed in men with prostate cancer without nodal or distant metastases. These strategies include the use of neo-adjuvant and adjuvant androgen deprivation, dose-escalation, hypofractionation, whole pelvic radiation therapy, incorporation of improved imaging, image- guided radiation therapy, and adjuvant systemic therapy. The evidence to date for these strategies is discussed, noting limitations in applying the results of reported trials to men treated in contemporary settings.

Results

A number of strategies have shown improvements in biochemical control using external beam radiotherapy. To date, only with the use of androgen deprivation therapy has this translated into improvements in disease specific and overall survival. This may reflect the long natural history of prostate cancer and high incidence of competing risks. Technological advances have enabled dose escalation with reduced toxicity, of paramount importance given the long natural history.

Results

The use of external beam radiation therapy in prostate cancer is evolving with numerous strategies incorporated to improve outcomes. The optimum dose and fractionation and use of androgen deprivation or systemic adjuvants for each man is unclear based on current evidence and prognostic and predictive parameters. Patient preferences play an important role in chosen therapy. It is hoped that future studies better capture all prostate cancer- and treatment- related morbidity to clarify the optimal therapy choices for each man with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Al-Mamgani A, Heemsbergen WD, Peeters STH et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685–691

    Article  PubMed  Google Scholar 

  2. Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16:274–283

    Article  PubMed  Google Scholar 

  3. Aluwini S, Pos F, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17:464–474

    Article  PubMed  Google Scholar 

  4. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041

    Google Scholar 

  5. Andriole GL, Crawford ED, Grubb RL, Buys SS et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, Strigari L (2017) Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol 35(17):1891–1897

    Article  CAS  PubMed  Google Scholar 

  7. Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15:1307–1316

    Article  CAS  PubMed  Google Scholar 

  8. Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40:769–782

    Article  CAS  PubMed  Google Scholar 

  9. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60(6):1244–1250

    Article  CAS  PubMed  Google Scholar 

  10. Barenttsz JO, Weinreb JC, Verma S et al (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49

    Article  Google Scholar 

  11. Beard C, Schultz D, Loffredo M et al (2006) Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low and intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66:403–407

    Article  PubMed  Google Scholar 

  12. Beckendorf V, Guerif S, Le Prise E, Cosset J-M, Bougnoux A et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5 year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063

    Article  PubMed  Google Scholar 

  13. Bill-Axelson A, Holmberg L, Garmo H et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. NEJM 370:932–942

    Article  CAS  PubMed  Google Scholar 

  14. Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527

    Article  CAS  PubMed  Google Scholar 

  15. Bolla M, Maingnon P, Carrie C et al (2016) Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991. J Clin Oncol 34(15):1748–1756

    Article  CAS  PubMed  Google Scholar 

  16. Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027

    Article  PubMed  Google Scholar 

  17. Bolla M, Van Tienhoven GV, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10 years results of an EORTC randomised study. Lancet Oncol 11:1066–1073

    Article  CAS  PubMed  Google Scholar 

  18. Bosco C, Bosnyak Z, Malmberg A et al (2015) Quantifying observational evidence for risk of fatal and nonfatal myocardial cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68:386–396

    Article  PubMed  Google Scholar 

  19. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  PubMed  Google Scholar 

  20. Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13

    Article  PubMed  Google Scholar 

  21. Briganti A, Abdollah F, Nini A et al (2012) Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 61(6):1132–1138

    Article  PubMed  Google Scholar 

  22. Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265

    Article  PubMed  Google Scholar 

  23. Catton C, Lukka H, Gu C-S, Martin J, Supiot S, Chung PW, Bauman GS et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1844–1890

    Article  Google Scholar 

  24. Chopra S, Toi A, Taback N et al (2012) Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 82:e441–e448

    Article  PubMed  Google Scholar 

  25. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk-adjusted mortality outcomes following primary surgery, radiation therapy, or androgen deprivation therapy for localized prostate cancer. Cancer 116:5226–5234

    Article  PubMed  Google Scholar 

  26. Crook J, Ludgate C, Malone S et al (2009) Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73(2):327

    Article  CAS  PubMed  Google Scholar 

  27. Crook JM, O’Callaghan CJ, Duncan G et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895–903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Crook JM, Raymond Y, Salhani D, Yang H, Esche B (1995) Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37:35–42

    Article  CAS  PubMed  Google Scholar 

  29. Curtis W, Khan M, Magnelli A, Stephans K, Tendulkar R, Xia P (2013) Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys 85:700–706

    Article  PubMed  Google Scholar 

  30. D’Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17):2420–2425

    Article  PubMed  CAS  Google Scholar 

  31. D’Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292:821–827

    Article  PubMed  Google Scholar 

  32. D’Amico AV, Renshaw AA, Cote K et al (2004) Impact of percentage of positive cores on prostate cancer specific mortality for patients with low or favourable-intermediate risk disease. J Clin Oncol 22:3726–3732

    Article  PubMed  Google Scholar 

  33. D’Amico AV, Renshaw AA, Sussman B, Chen MH (2005) Pretreatment PSA velocity and risk of death following external beam radiation therapy. JAMA 294:440–447

    Article  PubMed  Google Scholar 

  34. D’Amico AV, Whittington R, Malkowicz SB et al (1998) “Biochemical outcome after radical protatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    Article  PubMed  Google Scholar 

  35. Dang A, Kupelian PA, Cao M et al (2018) Image-guided radiotherapy for prostate cancer. Transl Androl Urol 7(3):308–320

    Article  PubMed  PubMed Central  Google Scholar 

  36. Dayes IS, Parpia S, Gilbert J, Julian JA, Davis IR, Levine MN, Sathya J (2017) Long-term results of a randomized trial comparing iridium implant plus external beam radiotherapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys 99(1):90–93

    Article  PubMed  Google Scholar 

  37. de Crevoisier R, Tucker SL, Dong L et al (2005) Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62:965–973

    Article  PubMed  Google Scholar 

  38. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbridge P, Logue J, Malik Z et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060

    Article  PubMed  PubMed Central  Google Scholar 

  39. Dearnaley DP, Jovic G, Syndikus I et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464–473

    Article  PubMed  Google Scholar 

  40. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353:267–272

    Article  CAS  PubMed  Google Scholar 

  41. Denham JW, Joseph D, Lamb DS et al. (2014) Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 15(10):1076–1089

    Article  CAS  PubMed  Google Scholar 

  42. Denham JW, Steigler A, Lamb DS et al (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10 year data from the TROG 96.01 randomised trial. Lancet Oncol 12(5):451–459

    Article  CAS  PubMed  Google Scholar 

  43. Duchesne GM, Peters LJ (1999) What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44:747–748

    Article  CAS  PubMed  Google Scholar 

  44. Eminowicz G, Dean C, Shoffren O et al (2013) Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy. Br J Radiol 87:0696

    Google Scholar 

  45. Fizazi K, Faivre L, Lesaunier F et al (2015) Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 16:787–794

    Article  CAS  PubMed  Google Scholar 

  46. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031

    Article  CAS  PubMed  Google Scholar 

  47. Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159

    Article  CAS  PubMed  Google Scholar 

  48. Goodwin JF, Sciewer MJ, Dean JL et al. (2013) A hormone-DNA repair circuit governs the response of genotoxic insult. Cancer Discovery 3(11):1254–1271

    Article  CAS  PubMed  Google Scholar 

  49. Gravis G, Boher JM, Joly F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of GETUG-AFU15 trial. Eur Urol 70:256–262

    Article  CAS  PubMed  Google Scholar 

  50. Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. NEJM 375(15):1415–1424

    Article  PubMed  Google Scholar 

  51. Hamstra DA, Mariados N, Sylvester J et al (2017) Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys 97(5):976–985

    Article  PubMed  Google Scholar 

  52. Haque R, Ulcickas Yood M, Xu X et al (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117(8):1233–1240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Harris V, Staffurth J, Esmail A et al (2015) Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(4):874–883

    Article  PubMed  Google Scholar 

  54. Heemsbergen WD, Al-Magmani A, Slot A, Dielwart MFH (2014) Long-term results of the Dutch randomised prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110:1104–1109

    Article  Google Scholar 

  55. Heemsbergen WD, Al-Magmani A, Witte MG, van Herk M, Lebesque JV (2013) Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: results from a randomized trial. Radiother Oncol 107:134

    Article  PubMed  Google Scholar 

  56. Heemsbergen WD, Al-Mamgani A, Witte MG et al (2010) Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 78(1):19–25

    Article  PubMed  Google Scholar 

  57. Heemsbergen WD, Hoogeman MS, Witte MG, Peeters STH, Inroccic L, Lebesque JV (2007) Increased risk of biochemical and clinical failure for prostate cancer patient with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78Gy. Int J Radiat Oncol Biol Phys 67(5):1418

    Article  CAS  PubMed  Google Scholar 

  58. Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68–80

    Article  PubMed  Google Scholar 

  59. Hoffman K, Voong R, Levy LB et al (2018) Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol 36(29):2943–2949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Hoffman KE, Voong KR, Pugh TJ, Skinner H et al (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88:1074–1084

    Article  PubMed  Google Scholar 

  61. Horwitz EM, Bae K, Hanks GE et al (2008) Ten-year follow-up of Radiation Oncology Therapy Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497–2504

    Article  CAS  PubMed  Google Scholar 

  62. Hoskin P, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103:217–222

    Article  PubMed  Google Scholar 

  63. Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395

    Article  CAS  PubMed  Google Scholar 

  64. Hsu A, Pawlicki T, Luxton G et al (2007) A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic nodes. Int J Radiat Oncol Biol Phys 68:898–902

    Article  PubMed  Google Scholar 

  65. Huggins C, Hodges CV (1941) Studies of prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 168:9–12

    Article  Google Scholar 

  66. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069

    Article  PubMed  Google Scholar 

  67. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multi-stage, platform randomised controlled trial. Lancet 387:1163–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Jones CU, Hunt D, McGowan DG et al (2011) Radiotherapy and short-term androgen deperivation for localized prostate cancer. N Engl J Med 365(2):107–118

    Article  CAS  PubMed  Google Scholar 

  69. Joseph DJ, Lamb D, Denham JW et al (2018) Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression and zoledronate for locally advanced prostate cancer. J Clin Oncol 36(6 Suppl):1

    Article  Google Scholar 

  70. Kaidar-Person O, Roach M 3rd, Crehange G (2013) Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys 86(4):600–605

    Article  PubMed  Google Scholar 

  71. Kalbasi A, Berman A, Swisher-McClure S et al (2015) Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1(7):897–906

    Article  PubMed  Google Scholar 

  72. Kaminski JML, Hanlon AL, Lim Joon D et al (2003) Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 57(1):24–28

    Article  CAS  PubMed  Google Scholar 

  73. Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456

    Article  CAS  PubMed  Google Scholar 

  74. Kellokumpu-Lehtinen P-LI, Hjalm-Eriksson M, Astrom L et al (2018) A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer. J Clin Oncol 36(Suppl 15):5000

    Article  Google Scholar 

  75. King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51:213–214

    Article  CAS  PubMed  Google Scholar 

  76. Kirkpatrick JP, Meyer JJ, Marks LB et al (2008) The linear quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18:240–243

    Article  PubMed  Google Scholar 

  77. Kishan AU, Cook RR, Ciezki JP et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA 319:896–905

    Article  PubMed  PubMed Central  Google Scholar 

  78. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, Shimizu S, Shinohara N, Harabayashi T, Miyasaka K (2002) Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys 53:1117–1123

    Article  PubMed  Google Scholar 

  79. Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L (2016) Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol 70(1):56–61

    Article  CAS  PubMed  Google Scholar 

  80. Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA (2007) Intrafraction motion of the prostate during external-beam radiotherapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69:419–425

    Article  PubMed  Google Scholar 

  81. Kuban DA, Levy LB, Cheung MR et al (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317

    Article  PubMed  Google Scholar 

  82. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74

    Article  PubMed  Google Scholar 

  83. Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52(3):704–711

    Article  CAS  PubMed  Google Scholar 

  84. Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL (2008) Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol 18:58–66

    Article  PubMed  Google Scholar 

  85. Kupelian PA, Langen KM, Zeiden OA et al (2006) Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 66:876–882

    Article  PubMed  Google Scholar 

  86. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A (2008) Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1146–1150

    Article  PubMed  Google Scholar 

  87. Langen KM, Willougby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, Kupelian PA (2008) Observations of real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 71:1084–1090

    Article  PubMed  Google Scholar 

  88. Lawton C, Desilvio M, Roach M, Uhl V et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655

    Article  PubMed  PubMed Central  Google Scholar 

  89. Lawton C, Lin X, Hanks G et al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long term update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98(2):296–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Lawton CAF, Michalski J, El-Naq I, Buyyounouski MK et al (2009) RTOG GU Radiation Oncology Specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387

    Article  PubMed  Google Scholar 

  91. Lee WR, Dignam JJ, Amin MA, Bruner DW, Low D, Swanson GP, Shah AB, D’Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325–2332

    Article  PubMed  PubMed Central  Google Scholar 

  92. Levine GN, D’Amcio AV, Berger P et al (2010) Androgen deprivation therapy in prostate cancer and cardiovascular risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association. Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 60:194–201

    Article  PubMed  PubMed Central  Google Scholar 

  93. Loblaw A, Liu S, Cheung P (2018) Stereotactic ablative body radiotherapy in patients with prostate cancer. Transl Androl Urol 7(3):330–340

    Article  PubMed  PubMed Central  Google Scholar 

  94. Marcello M, Ebert M, Haworth AM, Steigler A, Kennedy A, Joseph D, Denham J (2018) Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radiother Oncol 126:249–256

    Article  PubMed  Google Scholar 

  95. Mariados N, Sylvester J, Shah D, Karsch L et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971–977

    Article  PubMed  Google Scholar 

  96. Mason MD, Parulekar WR, Sydes MR et al (2015) Final report of the Intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 33(19):2143–2149

    Article  PubMed  PubMed Central  Google Scholar 

  97. Mattei A, Fueschel FG, Dhar NB et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited. Eur Urol 53:118–125

    Article  PubMed  Google Scholar 

  98. Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of gallium-PSMA Positron Emission Tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443

    Article  PubMed  Google Scholar 

  99. Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 68(3):530–534

    Article  PubMed  Google Scholar 

  100. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary J-P, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock M, Patel M, Gay H, Vigneault E, Winter K, Sandler H (2018) Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer. The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol (American Medical Association) 4(6):e180039

    Google Scholar 

  101. Moghanaki D, Turkbey B, Vapiwala N et al (2017) Advances in prostate cancer magnetic resonance imaging and positron emission tomography-computed tomography for staging and radiotherapy treatment planning. Semin Radiat Oncol 27:21–33

    Article  PubMed  Google Scholar 

  102. Mok G, Benz E, Vallee JP et al (2014) Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys 90(2):278–288

    Article  PubMed  Google Scholar 

  103. Monninkof EM, van Loon JWL, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, van den Bergh L, Isebaert S, McColl GM, Smeenk RJ, Noteboom J, Walraven I, Peeters PHM, van der Heide UA (2018) Standard prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol 127(1):74–80

    Article  Google Scholar 

  104. Morgan SC, Hoffman K, Loblaw A et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence based guideline. J Clin Oncol 36(34):3411–3430

    Article  CAS  PubMed Central  Google Scholar 

  105. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285

    Article  PubMed  Google Scholar 

  106. Mottet N, Bellmunt J, Bolla M, Briers E et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629

    Article  PubMed  Google Scholar 

  107. Nabid A, Carrier N, Martin A-G et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74:432–441

    Article  CAS  PubMed  Google Scholar 

  108. Nanda A, Chen MH, Moran BJ et al (2014) Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. Eur Urol 65:177–185

    Article  CAS  PubMed  Google Scholar 

  109. National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer. Version 4. https://wwwnccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 9 Oct 2018

  110. Nguyen RL, Je Y, Schutz FAB et al (2011) Association of andorgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359–2366

    Article  CAS  PubMed  Google Scholar 

  111. Nutting CM, Convery DJ, Cosgrove VP et al (2000) Reduction of small and large bowel irradiation using a optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656

    Article  CAS  PubMed  Google Scholar 

  112. O’Farrell S, Gamo H, Holmberg L et al (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251

    Article  PubMed  CAS  Google Scholar 

  113. Padhani AR, Khoo VS, Suckling J, Husband JE, Leach MO, Dearnaley DP (1999) Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys 44:525–533

    Article  CAS  PubMed  Google Scholar 

  114. Peeters STH, Lebesque JV, Heemsbergen WD et al (2006) Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 64(4):1151–1161

    Article  PubMed  Google Scholar 

  115. Pilepich MV, Winter K, Lawton CA et al (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61(5):1285–1290

    Article  CAS  PubMed  Google Scholar 

  116. Pisansky TM, Hunt D, Gomella LG et al (2015) Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation Therapy Oncology Group Randomized Clinical Trial 9910. J Clin Oncol 33(4):332–339

    Article  PubMed  Google Scholar 

  117. Polkinghorn WR, Parker JS, Lee MX et al (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3(11):1245–1253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31):3860–3868

    Article  PubMed  PubMed Central  Google Scholar 

  119. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  120. Pommier P, Chabaud S, Lagrange J, Richaud P, Le Prise E, Wagner J, Azria D, Beckendorf V, Suchaud J, Bernier V, Perol D, Carrie C (2016) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96(4):759–769

    Article  PubMed  Google Scholar 

  121. Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25(34):5366–5373

    Article  PubMed  Google Scholar 

  122. Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintography and 68 Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43(12):2114–2121

    Article  CAS  PubMed  Google Scholar 

  123. Rauscher I, Maurer T, Fendler WP et al (2016) 68 Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging 16:14

    Article  PubMed  PubMed Central  Google Scholar 

  124. Roach M 3rd, Bae K, Speight J et al (2008) Short-term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585–591

    Article  PubMed  Google Scholar 

  125. Roach M 3rd, Desilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic radiotherapy versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413. J Clin Oncol 21(10):1904–1911

    Article  PubMed  Google Scholar 

  126. Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UA, Navvab Z, Carrol PR (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28(1):33–37

    Article  PubMed  Google Scholar 

  127. Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974

    Article  PubMed  Google Scholar 

  128. Rodda A, Morris WJ, Hamm J, Duncan G (2017) ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(3):581–589

    Article  PubMed  Google Scholar 

  129. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):286–295

    Article  PubMed  Google Scholar 

  130. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler H, Taplin ME, Treadwell JR (2018) Clinically localized prostate cancer: aUA/ASTRO/SUO Guideline. Part II: Recommended approaches and detailed specific care options. J Urol 199:990–997

    Article  PubMed  Google Scholar 

  131. Sandler HM, Hu C, Rosenthal SA et al (2015) A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 33(suppl 18):abstr LBA5002

    Article  Google Scholar 

  132. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328

    Article  PubMed  Google Scholar 

  133. Shelton J, Rossi PJ, Chen H, Liu Y, Master VA, Jani AB (2011) Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. Pract Radiat Oncol 1:243–250

    Article  PubMed  Google Scholar 

  134. Sooriakuman P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wikland P (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (Clinical Research Ed) 348:g1502

    Google Scholar 

  135. Spratt DE, Vargas HA, Zumsetg ZS et al (2017) Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic node coverage. Eur Urol 71:37–43

    Article  PubMed  Google Scholar 

  136. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  138. Byrne TE (2005) A review of prostate motion with considerations for the treatment of prostate cancer. Med Dosim 30:155–161

    Article  PubMed  Google Scholar 

  139. Thompson I, Thrasher JB, Aus G et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(2007):2106–2131

    Article  PubMed  Google Scholar 

  140. Thompson IM, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 296(19):1329–1335

    Article  Google Scholar 

  141. Vogelius IR, Bentzen SM (2018) Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 100(4):858–865

    Article  PubMed  Google Scholar 

  142. Wang-chesebro A, Xia P, Coleman J et al (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiotherapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66:654–662

    Article  PubMed  Google Scholar 

  143. Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, Lund J-A, Tasdemir I, Hoyer M, Wiklund F, Fossa SD, For the Scandinavian Prostate Cancer Group Study 7 and the Swedish Association for Urological Oncology 3 (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): and open randomised phase III trial. Lancet 373:301–308

    Article  CAS  PubMed  Google Scholar 

  144. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with post-operative undetectable prostate-specific antigen: ARO 96-02/AOU AP 09/95. J Clin Oncol 27(18):2924–2930

    Article  PubMed  Google Scholar 

  145. Willougby TR, Kupelian PA, Pouliot J et al (2006) Target localization and real-time tracking using Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 65:528–534

    Article  Google Scholar 

  146. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. NEJM 367:203–213

    Article  CAS  PubMed  Google Scholar 

  147. Zaorsky NG, Keith SW, Shaikh T et al (2016) Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities. Am J Clin Oncol 41(4):409–415

    Google Scholar 

  148. Zapatero A, Guerrero A, Maldonado X et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16:320–327

    Article  CAS  PubMed  Google Scholar 

  149. Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28:1508–1513

    Article  PubMed  PubMed Central  Google Scholar 

  150. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876–881

    Article  CAS  PubMed  Google Scholar 

  151. Ziehr DR, Chen MH, Zhang D et al (2015) Association of androgen-deprivation therapy with excess cardiac-specific mortality. BJU Int 116:358–365

    Article  CAS  PubMed  Google Scholar 

  152. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28(7):1106–1111

    Article  PubMed  PubMed Central  Google Scholar 

  153. Zietman AL, Nakfoor BM, Prince EA et al (1997) The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumour: an in vitro and in vivo study. Cancer J Sci Am 3:31–36

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Princess Alexandra Raymond Terrace (ROPART), 31 Raymond Terrace, South Brisbane, QLD, Australia

    Tiffany Daly

Authors
  1. Tiffany Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The author was solely responsible for the preparation of this manuscript.

Corresponding author

Correspondence to Tiffany Daly.

Ethics declarations

Conflict of interest

The author has no conflict of interest to declare.

Ethical standards

This review includes no person-level information and therefore no consent or ethical committee review was required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daly, T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J Urol 38, 565–591 (2020). https://doi.org/10.1007/s00345-019-02661-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-019-02661-6

Keywords

Search

Navigation